PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25335408-1 2014 The goal of this work was to study cytochrome-450 (CYP) 2C9 (CYP2C9) gene polymorphism in patients with tuberculosis (TB) and its meaning for development, progress, and outcome of TB, for the pharmacokinetics of the antituberculosis antibiotic rifampicin on the basis of the southern region of Ukraine. Rifampin 244-254 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 35-59 25335408-1 2014 The goal of this work was to study cytochrome-450 (CYP) 2C9 (CYP2C9) gene polymorphism in patients with tuberculosis (TB) and its meaning for development, progress, and outcome of TB, for the pharmacokinetics of the antituberculosis antibiotic rifampicin on the basis of the southern region of Ukraine. Rifampin 244-254 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 61-67 21292004-6 2011 NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4alpha in the presence of rifampicin. Rifampin 121-131 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 23852652-8 2013 Strong CYP3A or CYP2C9 inducers (e.g. rifampicin) would be expected to decrease the exposure to ospemifene. Rifampin 38-48 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 16-22 21930825-3 2011 Statistically significant induction of CYP1A2 (2.1-, 2.9-, and 2.2-fold), CYP2B6 (1.8-, 2.4-, and 4-fold), and CYP2C9 (1.3-, 1.8-, and 2.6-fold) was observed after NFV, RTV, or RIF treatment, respectively (as expected, CYP2D6 was not induced). Rifampin 177-180 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-117 23974699-7 2013 CYP1A2 and CYP2D6 enzyme activities showed no significant changes, and CYP2C9 enzyme activity was increased with rifampicin administration, with a tendency toward statistical significance. Rifampin 113-123 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 71-77 20086032-7 2010 Mutational studies showed that the HNF4alpha sites are needed for up-regulation of the CYP2C8 and CYP2C9 promoters by rifampicin. Rifampin 118-128 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 98-104 20086032-3 2010 In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression. Rifampin 138-148 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 183-189 20086032-8 2010 Furthermore, silencing of HNF4alpha abolished transactivation of the CYP2C8 and CYP2C9 promoters by rifampicin. Rifampin 100-110 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 80-86 19369937-9 2009 But the difference in activity levels between the CYP2C9*1/*1 and *3/*3 genotypes before the administration of rifampin was sixfold. Rifampin 111-119 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 50-56 19202563-3 2009 Clotrimazole, rifampin, ritonavir, phenytoin, and phenobarbital induced CYP2C9 consistent with previous findings for CYP3A4. Rifampin 14-22 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 72-78 19515014-10 2009 CYP2C9 is subject to induction by rifampin, phenobarbital, and dexamethasone, indicating the involvement of pregnane X receptor, constitutive androstane receptor and glucocorticoid receptor in the regulation of CYP2C9. Rifampin 34-42 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 19515014-10 2009 CYP2C9 is subject to induction by rifampin, phenobarbital, and dexamethasone, indicating the involvement of pregnane X receptor, constitutive androstane receptor and glucocorticoid receptor in the regulation of CYP2C9. Rifampin 34-42 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 211-217 19202563-6 2009 In 17 donors, rifampin increased mean basal CYP2C9 activity from 59 +/- 43 to 143 +/- 68 pmol/mg protein/min; fold induction ranged from 1.4- to 6.4-fold. Rifampin 14-22 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 44-50 15919766-2 2005 Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/PXR site -1839 bp upstream of the translation start site. Rifampin 183-193 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 150-156 15919766-8 2005 Mutation of the two HNF4alpha binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4alpha, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR. Rifampin 210-220 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 86-92 15676042-1 2005 AIMS: To investigate the potential induction by rifampicin of intestinal CYP2C8, CYP2C9, CYP2D6 and CYP3A4 using preparations of human enterocytes. Rifampin 48-58 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 81-87 15676042-11 2005 Induction of intestinal CYP2C8 and CYP2C9 might contribute in part to rifampicin - mediated drug interactions, in addition to their hepatic counterparts and intestinal and hepatic CYP3A4. Rifampin 70-80 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 35-41 12882588-10 2003 Rifampicin also induces CYP2C-mediated metabolism and thus reduces the plasma concentrations of, for example, the CYP2C9 substrate (S)-warfarin and the sulfonylurea antidiabetic drugs. Rifampin 0-10 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 114-120 14600250-0 2004 Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. Rifampin 29-39 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 19-25 14600250-2 2004 Several studies have reported that certain drugs such as rifampicin and phenobarbital induce CYP2C9, but the molecular basis for this induction remains unknown. Rifampin 57-67 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 93-99 14600250-3 2004 In the present study, we demonstrate that the human pregnane X receptor (hPXR) mediates induction of CYP2C9 by the prototype drugs rifampicin, hyperforin (found in St. John"s Wart), and phenobarbital. Rifampin 131-141 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 101-107 14600250-4 2004 Deletion and mutagenesis studies with luciferase reporter constructs showed that a functional PXR-responsive element located -1839/-1824 base pairs upstream from the translation start site was the primary binding site mediating the rifampicin induction of CYP2C9. Rifampin 232-242 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 256-262 14600250-6 2004 Mutational analysis of 3- and 12-kilobase CYP2C9 promoter fragments indicated that this proximal binding site was essential for rifampicin inducibility, although a cooperative effect could be attributed to a second CAR-RE located at -2899/-2883. Rifampin 128-138 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 14600250-7 2004 In summary, we have demonstrated rifampicin induction of CYP2C9 promoter constructs that is consistent with the magnitude of induction of CYP2C9 protein and mRNA reported in vivo and in primary human hepatocytes, and we have identified the cis-element essential for this response. Rifampin 33-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 57-63 14600250-7 2004 In summary, we have demonstrated rifampicin induction of CYP2C9 promoter constructs that is consistent with the magnitude of induction of CYP2C9 protein and mRNA reported in vivo and in primary human hepatocytes, and we have identified the cis-element essential for this response. Rifampin 33-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 138-144 14600250-8 2004 This is the first report to demonstrate that the nuclear receptor PXR mediates induction of CYP2C9 with rifampicin, phenobarbital, and hyperforin. Rifampin 104-114 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 92-98 15364537-8 2004 Primary cultures of hepatocytes were treated with beta-naphthoflavone, an inducer of CYP1A2, phenobarbital or rifampin, both of which induce CYP2B6, CYP2C9, CYP2C19, and CYP3A4, albeit it to different extents. Rifampin 110-118 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 149-155 14722322-9 2004 Treatment with 10 microM rifampin resulted in increases in CYP3A4 mRNA (17-fold) and activity (6-beta-hydroxytestoterone formation, 9-fold); and in CYP2C9 mRNA (4-fold) and activity (4"-hydroxydiclofenac formation, 2-fold). Rifampin 25-33 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 148-154 15001966-12 2004 CONCLUSION: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Rifampin 35-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 177-183 14534520-8 2003 CONCLUSION: The effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide suggests that rifampin affects the disposition of gliclazide in humans, possibly by the induction of cytochrome P450 2C9. Rifampin 108-116 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 195-214 12130704-5 2002 Parallel increases in CYP2C mRNAs, measured by Northern blotting and/or RNase protection, were found in rifampicin-treated hepatocytes, with CYP2C8, CYP2C9, and CYP2C19 transcripts exhibiting increases of 688 +/- 635, 207 +/- 49, and 230 +/- 60%, respectively, versus an 8.8-fold enhancement of CYP3A4 mRNA levels. Rifampin 104-114 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 149-155 12426514-3 2002 Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs. Rifampin 0-8 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 91-97 12426514-3 2002 Rifampin (INN, rifampicin), a potent enzyme inducer of CYP-mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs. Rifampin 15-25 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 91-97 11136298-7 2000 CONCLUSIONS: The effects of rifampicin on the pharmacokinetics of glimepiride suggest that rifampicin induced the CYP2C9-mediated metabolism of glimepiride and thereby slightly increased its systemic clearance. Rifampin 28-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 114-120 11181490-4 2001 Compounds known to activate the pregnane X receptor (PXR) such as rifampicin, or the constitutively activated receptor (CAR) such as phenobarbital, induced CYP2C8, CYP2C9, and to a lesser extent CYP2C19 mRNAs and proteins. Rifampin 66-76 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 164-170 11181490-6 2001 The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital. Rifampin 71-81 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 43-49 11181490-6 2001 The concentration dependence of CYP2C8 and CYP2C9 mRNAs in response to rifampicin and phenobarbital paralleled that of CYP3A4 and CYP2B6, the maximum accumulation being reached with 10 microM rifampicin and 100 microM phenobarbital. Rifampin 192-202 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 43-49 11181490-9 2001 Furthermore, dexamethasone, which has been recently shown to up-regulate PXR and CAR expression through the glucocorticoid receptor, potentiated CYP2C8 and CYP2C9 mRNA induction in response to rifampicin and phenobarbital. Rifampin 193-203 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 156-162 11679585-3 2002 In previous work, we have shown that CYP2C9 is inducible in primary human hepatocytes by xenobiotics including dexamethasone, rifampicin, and phenobarbital. Rifampin 126-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 37-43 11679585-8 2002 Identification of these functional elements provides rational mechanistic basis for CYP2C9 induction by dexamethasone (submicromolar concentrations), and by phenobarbital and rifampicin, respectively. Rifampin 175-185 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 84-90 11714868-5 2001 The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA. Rifampin 119-127 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 207-213 11406737-12 2001 The mechanism underlying the interaction between rifampin and glyburide is probably induction of either CYP2C9 or P-glycoprotein or both. Rifampin 49-57 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 104-110 11735605-5 2001 On the other hand, rifampicin is a nonspecific inducer of CYP-mediated metabolism (especially of CYP2C9, CYP2C19 and CYP3A4) and may therefore cause therapeutic failure of other coadministered drugs by increasing their clearance. Rifampin 19-29 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 97-103 11136298-7 2000 CONCLUSIONS: The effects of rifampicin on the pharmacokinetics of glimepiride suggest that rifampicin induced the CYP2C9-mediated metabolism of glimepiride and thereby slightly increased its systemic clearance. Rifampin 91-101 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 114-120 10924340-4 2000 In parallel, IL-6 decreases both rifampicin- and phenobarbital-mediated induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4. Rifampin 33-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 101-107 10673364-4 2000 Using an RT-competitive PCR (RT-cPCR) with beta-actin as the standard in this study, the constitutive and rifampicin (RFP)-induced expression of CYP3A4, CYP2C9, CYP2E1, and CYP1A2 mRNA in the HepG2 cells could be quantitatively and reproducibly determined. Rifampin 106-116 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 153-159 20702214-3 1990 Phenobarbital and rifampicin were found to increase the levels of P-450 IIC8, 9, 10 mRNA and protein while troleandomycin and 3-methylcholanthrene were ineffective. Rifampin 18-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 66-79 2200675-5 1990 Phenobarbital and rifampicin increased P-450 IIC8/9/10 mRNA transcripts and the corresponding protein, while 3-methylcholanthrene was ineffective. Rifampin 18-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 39-54 9663807-3 1998 CYP2C9 activity in vivo is inducible by rifampicin. Rifampin 40-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 9010637-5 1997 The inducers of CYP3A and/or CYP2C9 (e.g. rifampicin and phenytoin) are likely to alter the disposition of seratrodast. Rifampin 42-52 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 29-35 7614688-7 1995 Treatment of cynomolgus monkeys with rifampicin induced hepatic cytochromes P450 related to human CYP3A4 and CYP2C9/10 without inducing CYP1A1 or CYP1A2. Rifampin 37-47 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 109-115 7614688-12 1995 Since cytochromes P4503A and/or P4502C are constitutively expressed in cynomolgus monkey hepatic microsomes, and upon induction with rifampicin are associated with an increased metabolic activation of IQ but not MeIQx, it appears that CYP3A and/or CYP2C are the isoform(s) showing the selective substrate specificity in the metabolic activation of IQ over MeIQx. Rifampin 133-143 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 248-253 29368402-3 2018 The parameters for cytochrome P450 (CYP) 3A and CYP2C9 induction by rifampicin were similarly optimized using clinical DDI data with midazolam and tolbutamide as probe substrates, respectively. Rifampin 68-78 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 48-54 35370222-1 2022 We encountered cases in which the anticoagulant effects of warfarin (CYP2C9 substrate) were reversibly attenuated by the concomitant administration of rifampicin or bosentan, which are potent pregnane X receptor (PXR) ligands. Rifampin 151-161 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 69-75 34872459-11 2021 Patients with tuberculosis with older age and genetic polymorphism of CYP3A4, CYP2C9, and CYP2C19 who received long-term rifampicin treatment were more likely to have antituberculosis drug-induced liver injury. Rifampin 121-131 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 78-84 33542643-2 2021 Due to rifampin"s strong induction of CYP2C9, most cases could not attain the target international normalized ratio (INR) despite warfarin dose escalation. Rifampin 7-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 38-44 35062050-13 2022 In the NAFLD model, Omeprazole maintained an expected induction of CYP1A1, however Phenytoin and Rifampicin showed elevated induction of CYP2B6 and CYP2C9 compared to healthy cultures. Rifampin 97-107 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 148-154 31676845-7 2019 We also demonstrated that matured Huh7s can be used for drug induction studies, where CYP3A4, CYP1A2, CYP2C9, and CYP2C19 inductions were achieved following rifampicin treatment. Rifampin 157-167 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 102-108 31420941-2 2019 We previously constructed a physiologically-based pharmacokinetic (PBPK) model of rifampicin accounting for the components for the induction of cytochrome P450 (CYP) 3A/CYP2C9 and the inhibition of organic anion transporting polypeptide 1B (OATP1B). Rifampin 82-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 169-175 28173639-5 2017 In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 muM bosentan+200 muM rifampin. Rifampin 133-141 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 30-36 30105453-1 2018 PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. Rifampin 89-97 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 124-130 30105453-14 2018 CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects. Rifampin 64-72 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 99-105 29569712-1 2018 Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism. Rifampin 0-8 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 164-170 29569712-1 2018 Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism. Rifampin 0-8 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 188-194 28157069-0 2017 Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases : . Rifampin 74-84 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 24-30 28157069-3 2017 To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin. Rifampin 81-91 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 28157069-3 2017 To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin. Rifampin 185-195 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 26658225-5 2016 The EC50 of rifampin for CYP3A4 and CYP2C9 was up to 10-fold lower in HepatoPac than the monocultures. Rifampin 12-20 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 36-42 26759747-2 2016 Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19. Rifampin 0-8 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 193-199 26549688-6 2016 RT-PCR analysis showed that PXR SUMOylation in presence of rifampicin also enhances the endogenous expression levels of key PXR-regulated genes like CYP3A4, CYP2C9, MDR1 and UGT1A1. Rifampin 59-69 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 157-163